Ascendis Pharma A/S (NASDAQ:ASND) Given New $200.00 Price Target at Cantor Fitzgerald

Ascendis Pharma A/S (NASDAQ:ASND) had its price objective upped by Cantor Fitzgerald from $170.00 to $200.00 in a research note issued to investors on Tuesday,Benzinga reports. Cantor Fitzgerald currently has an overweight rating on the biotechnology company’s stock.

Other equities analysts have also recently issued reports about the stock. TD Cowen cut their target price on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a research note on Friday, November 15th. The Goldman Sachs Group upped their price objective on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. JPMorgan Chase & Co. lifted their target price on Ascendis Pharma A/S from $167.00 to $168.00 and gave the stock an “overweight” rating in a research report on Thursday, February 13th. StockNews.com raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Finally, Morgan Stanley set a $180.00 price objective on Ascendis Pharma A/S in a research report on Tuesday, February 18th. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $202.36.

Ascendis Pharma A/S Price Performance

Ascendis Pharma A/S stock opened at $151.53 on Tuesday. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $161.00. The firm has a fifty day moving average price of $135.06 and a two-hundred day moving average price of $133.54. The firm has a market cap of $9.20 billion, a price-to-earnings ratio of -21.34 and a beta of 0.64.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.64. As a group, sell-side analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Ascendis Pharma A/S during the 4th quarter worth about $28,000. Wilmington Savings Fund Society FSB bought a new stake in Ascendis Pharma A/S during the third quarter worth about $30,000. Jones Financial Companies Lllp increased its holdings in shares of Ascendis Pharma A/S by 394.0% during the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock worth $34,000 after buying an additional 197 shares in the last quarter. Blue Trust Inc. raised its stake in shares of Ascendis Pharma A/S by 415.2% in the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company’s stock valued at $56,000 after acquiring an additional 328 shares during the last quarter. Finally, Groupama Asset Managment acquired a new position in shares of Ascendis Pharma A/S in the 3rd quarter worth approximately $60,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.